SG10201807631SA - Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions - Google Patents

Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Info

Publication number
SG10201807631SA
SG10201807631SA SG10201807631SA SG10201807631SA SG10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA SG 10201807631S A SG10201807631S A SG 10201807631SA
Authority
SG
Singapore
Prior art keywords
preparation
particles
liquid medium
cross flow
flow filtration
Prior art date
Application number
SG10201807631SA
Inventor
Hans Peter Niedermann
Heiko Bothe
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of SG10201807631SA publication Critical patent/SG10201807631SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

Use of Liquid Medium Exchange by Cross Flow Filtration in the Preparation of Drug Suspensions Disclosed is a method of making particles of a drug wherein use is made of diafiltration. The diafiltration can be with anti-solvent, in which case a precipitate is obtained of particles as such. The diafiltration can also be with a pharmaceutically acceptable suspension medium. In that case several process steps of isolating, drying, transporting of particles can be avoided, because the suspension resulting from the synthesis of the particles is directly turned into a final drug product formulation. (No suitable figure)
SG10201807631SA 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions SG10201807631SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161431942P 2011-01-12 2011-01-12

Publications (1)

Publication Number Publication Date
SG10201807631SA true SG10201807631SA (en) 2018-10-30

Family

ID=45478323

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013053764A SG191963A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
SG10201807631SA SG10201807631SA (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013053764A SG191963A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Country Status (10)

Country Link
US (1) US9066864B2 (en)
EP (1) EP2663287A1 (en)
JP (1) JP5934719B2 (en)
CN (1) CN103347499B (en)
AU (1) AU2012206621B2 (en)
BR (1) BR112013016851B1 (en)
CA (1) CA2823972C (en)
MX (1) MX346749B (en)
SG (2) SG191963A1 (en)
WO (1) WO2012095439A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478959B2 (en) * 2016-09-07 2019-03-06 株式会社富士薬品 System and method for producing a particle-containing composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373131C (en) 1999-05-12 2004-11-02 Metabolix, Inc. Methods for purifying polyhydroxyalkanoates
WO2001021290A1 (en) * 1999-09-17 2001-03-29 Danish Separation Systems As A method and an apparatus for continuous cross-flow diafiltration
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
IL162183A0 (en) * 2001-12-21 2005-11-20 Celator Technologies Inc Polymer-lipid delivery vehicles and methods for the preparation thereof
WO2003063877A1 (en) * 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
PL208585B1 (en) * 2002-10-25 2011-05-31 Intervet Int Bv Prolonged release pharmaceutical composition
ITMI20022674A1 (en) 2002-12-18 2004-06-19 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF STERILE FORMULATIONS BASED ON MICRONIZED CRYSTALLINE PHARMACEUTICAL ACTIVE SUBSTANCES TO BE ADMINISTERED AS WATER SUSPENSION BY INHALATION.
DK2509634T3 (en) * 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles

Also Published As

Publication number Publication date
SG191963A1 (en) 2013-08-30
US20130281425A1 (en) 2013-10-24
BR112013016851A2 (en) 2016-10-04
MX346749B (en) 2017-03-29
WO2012095439A1 (en) 2012-07-19
CN103347499B (en) 2017-04-05
US9066864B2 (en) 2015-06-30
CA2823972C (en) 2019-05-28
AU2012206621A1 (en) 2013-07-04
CN103347499A (en) 2013-10-09
BR112013016851B1 (en) 2021-08-31
AU2012206621B2 (en) 2017-04-27
MX2013008118A (en) 2013-08-12
JP5934719B2 (en) 2016-06-15
CA2823972A1 (en) 2012-07-19
JP2014502624A (en) 2014-02-03
EP2663287A1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
SE0800304L (en) Process for preparing ethanol from sugar-containing solution / suspension by fermentation
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
WO2012094425A3 (en) Biological methods for preparing adipic acid
HK1200207A1 (en) Process line for the production of freeze-dried particles
WO2012171026A3 (en) Methods for high yield virus production
NZ617308A (en) Aqueous process for preparing protein isolate and hydrolyzed protein from an oilseed
MX2014000753A (en) Process for producing viral antigen and vaccines.
MX341663B (en) Organic compound nanopowder, production method therefor, and suspension.
WO2012096458A3 (en) Process for preparation of phenyl carbamate derivatives
HK1199242A1 (en) Process for the production of 1,3-butadiene 13-
EA201270409A1 (en) METHOD OF MANUFACTURE OF INTERIM ARTICLES PRODUCTS
WO2015148736A8 (en) Methods of preparing a poloxamer for use in cell culture medium
SG10201807631SA (en) Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
IN2012MU03517A (en)
MX350430B (en) Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-m ethyl-pentanoic acid compounds.
MX2013013436A (en) Substituted indole derivatives for the treatment of immunological disorders.
WO2015101243A8 (en) Reproduction of female sterility line and technology of hybrid seed production
MY169503A (en) Preparation method of new recombinant antibacterial polypeptide medicine
WO2013023254A8 (en) Method for the recovery of magnesium sulphate and production of magnesium oxide
JP2014502624A5 (en)
WO2013046233A3 (en) Process for the preparation of octreotide acetate
WO2013072935A3 (en) Process for the preparation of silodosin
RU2012133403A (en) METHOD FOR PRODUCING MICROCapsules OF MEDICINES OF THE CEPHALOSPORIN GROUP IN KONJAC GUM IN BUTYL ALCOHOL
WO2011037367A3 (en) Highly-efficient manufacturing method of induced pluripotent stem cells and induced pluripotent stem cells produced by the method
WO2012081036A3 (en) A process for preparation of 4,4'-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione)